BioWorld: Japan Eyes a “Third Way” as U.S. Policy and China’s Rise Reshape Biotech
At BioJapan 2026 in Yokohama, BioWorld reported that global disruptions are opening a path for Japan to use its scientific strengths to develop and commercialize new drugs. These include U.S. drug pricing policy, China’s rapid rise, and the growing role of AI and health data. Speakers stressed that strong science alone won’t be enough. Incubate Coalition Japan joined the conversation on how investment, policy and partnerships can help Japan seize the moment.

Comments